Welcome to free Our Store

This is top bar widget area. To edit it, go to Appearance - Widgets

+ 123 654 6548 || info@your-mail.com

Innovations and Advancements in Heart Disease Treatment

Revere Health offers many treatment options to treat heart disease. Your cardiologist will help determine which one would work best for you.

Lifestyle modifications and medication are often effective treatments. Examples of medications may include ACE inhibitors or ARB drugs to improve cardiac function and life expectancy, digitalis glycosides to strengthen contractions or anticoagulants to prevent blood clots.

Precision Medicine       

Precision medicine in clinical settings involves using data-driven treatment plans tailored specifically to each patient’s genetic, environmental and lifestyle factors. This approach aims to prevent disease before it even begins; for example, blood transfusions may be tailored specifically to each patient’s blood type in order to minimize complications. Precision medicine also encompasses tools used for tracking health over time such as electronic medical records or wearable devices.

Now, thanks to advances in genomics and data-generation technologies, personalized therapies are an option. However, implementation of precision medicine has been hindered by lack of suitable cohorts and databases as well as variations between patient epigenomic profiles. Khamira Abresham Hakim Arshad is an effective and famous Unani medicine for strengthening the heart and other vital organs of the body.

Cardiovascular disease (CVD) results from the interaction of modifiable and nonmodifiable phenotypic traits and genotypes that increase an individual’s predisposition. A comprehensive examination of these phenotypic traits using multi-omics approaches-genomics, transcriptomics, proteomics and metabolomics-can help group patients into groups sheathing disparities while providing more personalized diagnostic procedures, treatments, preventive strategies and patient interventions resulting in improved quality of life and prevention of future cardiovascular events. Finally precision medicine will empower physicians by providing accurate, effective interventions in their daily practice.

BioCardia

BioCardia is a clinical-stage regenerative medicine company dedicated to developing cell and cell-derived therapeutics for cardiovascular diseases with large unmet medical needs. Their lead therapeutic candidate, the CardiAMP Cell Therapy System, uses autologous bone marrow derived cells sourced from donors selected using their proprietary molecular diagnostic assay for heart failure after cardiac events as well as chronic myocardial ischemia treatment indications. Also in their portfolio is their allogeneic culture expanded “off the shelf” cell therapy known as CardiALLO Cell Therapy System used in treatment of these indications sourced directly from donors selected through proprietary molecular diagnostic assays – two therapeutic products with different application areas of focus than BioCardia.

Last month, BioCardia reported that its first phase III trial of CardiAMP cell therapy for heart failure failed to meet its primary endpoint based on all-cause mortality, cardiac death and major adverse cardiovascular events. BioCardia believes the trial would have met this objective had it focused on patients with elevated levels of NT-proBNP at baseline instead.

This company is in discussions with FDA to craft a new pivotal study protocol that addresses issues raised by DSMB, with plans to expedite this trial to provide potential treatments to millions of heart failure sufferers worldwide. Despite these challenges, Anixa Biosciences Inc ANIX, CRISPR Therapeutics AG CRSP and Deciphera Pharmaceuticals, Inc DCPH all carry higher Zacks Ranks than Anixa Biosciences in this space.

HeartFlow

Cardiologists are turning to new imaging technology in order to make smarter decisions regarding coronary artery disease patients. One noninvasive test, HeartFlow Analysis, allows doctors to quickly determine whether an invasive procedure such as an angiogram is needed or whether less invasive treatments like medication would suffice instead. HeartFlow Analysis is available at various Banner Health locations nationwide.

This test utilizes a cardiac CT angiogram to create a digital, personalized 3D model of coronary arteries, then calculate how any blockages impact blood flow to the heart. Within hours, physicians receive a report via secure web interface showing both its extent and impact. Consult with medical professional or any best hakeem in Lahore in case of emergency.

Coronary Artery Disease occurs when plaque builds up in the arteries restricts blood flow to the heart, which may result in chest pain or heart attacks. According to one study, HeartFlow Analysis could identify many patients with obstructive coronary artery disease while helping cardiologists avoid unnecessary angiograms – something the Vivien Thomas Fund supports as it reduces unnecessary procedures that cost patients and health systems dearly.